Ongoing adjuvant phase III trials examine dual checkpoint inhibition with nivolumab and the LAG-3 inhibitor relatlimab in completely resected stage III disease in the Relativity-098 trial (NCT05418972), the combination of cemiplimab (anti-PD-1) and fianlimab (anti-LAG-3) in patients with stage IIC-IV melanoma (NCT05608291), and the co-formulation of pembrolizumab and vibostolimab (inhibitor of T-cell immunoreceptor with Ig and ITIM domains (TIGIT)) in resected stage II–IV disease in the Keyvibe-010 trial (NCT05665595). Here, LAG3 is linked to melanoma.